Stryker Corporation 2008 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2008. Stryker Corporation is a leading global medical technology company with two primary reportable segments: Orthopaedic Implants (joint replacement, trauma, spine, craniomaxillofacial) and MedSurg Equipment (surgical equipment, navigation, endoscopy, patient handling). The company operates in over 100 countries, with 64% of sales generated domestically and 36% internationally.
Key Financial Metrics
| Metric (in millions, except per share) | 2008 | 2007 |
|---|---|---|
| Net Sales | $6,718.2 | $6,000.5 |
| Gross Profit | $4,586.8 | $4,135.3 |
| Operating Income | $1,519.0 | $1,307.3 |
| Net Earnings (Continuing Ops) | $1,147.8 | $986.7 |
| Diluted EPS (Continuing Ops) | $2.78 | $2.37 |
| Operating Cash Flow | $1,175.9 | $1,028.3 |
| Long-Term Debt | $20.5 | $16.8 |
| Cash & Marketable Securities | $2,195.6 | $2,410.8 |
| Working Capital | $3,517.2 | $3,571.9 |
Margins: Gross margin was 68.3% in 2008 (down from 68.9% in 2007). Operating margin was 22.6% (up from 21.8%).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% year-over-year. Growth was driven by an 11% increase in Orthopaedic Implants sales and a 14% increase in MedSurg Equipment sales. On a constant currency basis, sales grew 11%.
- Profitability: Net earnings from continuing operations rose 16% to $1,147.8 million. Adjusted net earnings (excluding restructuring and impairment charges) increased 17%.
- Restructuring Charges: The company recorded $34.9 million in restructuring charges in 2008 (none in 2007), primarily related to simplifying its Japanese distribution business and reducing development efforts for Sightline Technologies products.
- Share Repurchases: Stryker completed a $1,000 million share repurchase program in 2008, buying back 17.4 million shares. A new $250 million authorization was announced in Q4 2008.
- Inventory: Days sales in inventory increased to 155 days from 137 days in 2007, attributed to stocking for anticipated product launches.
Guidance, Outlook, and Risks
2009 Outlook: Management projects diluted net earnings per share for 2009 in the range of $3.12 to $3.22 (a 10-14% increase over 2008 adjusted EPS). Constant currency net sales growth is expected to be between 6% and 9%. Management anticipates an unfavorable foreign currency impact of 3.5% to 4.5% on full-year 2009 sales.
Management Commentary: The company noted a significant contraction in hospital capital budgets in Q4 2008 due to the economic slowdown, depressing demand for certain MedSurg Equipment products. There is also a risk of a slowdown in elective orthopaedic procedures.
Risks and Contingencies:
- Legal & Regulatory: The company is cooperating with multiple investigations, including a DOJ inquiry regarding OP-1 sales and off-label promotion, an HHS subpoena regarding consulting fees to surgeons, and an SEC/DOJ inquiry into potential Foreign Corrupt Practices Act violations.
- FDA Compliance: Stryker received FDA warning letters in 2008 and 2007 regarding quality system compliance at facilities in Massachusetts, Ireland, and New Jersey.
- Liquidity: The company holds $166.8 million in par value of Auction Rate Securities (ARS) which have experienced failed auctions. While the company does not expect this to impact operations, these assets are classified as non-current until liquidity is restored.
Key Facts for Investor Verification
- Restructuring Impact: Verify the execution of the $34.9 million restructuring plan, specifically the timeline for asset disposals in Japan and severance payments expected in 2009.
- Legal Exposure: Monitor the resolution of the DOJ and HHS investigations regarding marketing practices and consulting agreements, as well as the outcome of the FDA compliance issues.
- ARS Liquidity: Track the status of the $166.8 million in illiquid Auction Rate Securities and the effectiveness of the "Rights" agreement with UBS to sell them at par.
- 2009 Guidance: Assess whether the projected 6-9% constant currency sales growth can be maintained given the noted economic headwinds and reduced hospital capital spending.
- Inventory Levels: Watch for changes in inventory days (currently 155) to ensure the buildup for new product launches does not lead to significant write-downs if demand softens.